Skip to content
2000
Volume 23, Issue 9
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

PI3K is an important anticancer target as it controls cellular functions such as growth, transformation, proliferation, motility and differentiation. Plasma cell cancer (multiple myeloma) occurs more than 10% among all haematological malignancies and accounts for 2% of all cancer-related deaths each year, it is mainly regulated by PI3K/AKT signaling cascade. Quinazoline derivatives have been reported as promising PI3K inhibitors. Lapatinib, afatinib, gefitinib, erlotinib, idelalisib and copanlisib are quinazoline-based, FDA-approved PI3K inhibitors, while compounds like NVPBYL719, GDC-0032, AZD8186, AZD-6482, etc. are under different stages of clinical trials. In light of the above-mentioned facts, in the present study, we have reported different synthetic approaches, mechanisms of anticancer action, and structure-activity relationship analysis of reported quinazoline derivatives as PI3K inhibitors to help researchers working in the field in designing better and isoform-selective PI3K inhibitors.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520623666230116163424
2023-05-01
2025-03-15
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520623666230116163424
Loading

  • Article Type:
    Review Article
Keyword(s): Cancer; mechanism of action; mTOR pathways; PI3K; quinazoline; SAR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test